Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

China Chengtong accelerates the integration of its papermaking business. Yueyang Forest & Paper plans to "recover" old assets for 1.28 billion.

① China Chengtong integrates the papermaking business, mcc meili cloud computing industry investment and yueyang forest & paper are both taking action; ② yueyang forest & paper plans to acquire a pulp company that was divested years ago for 1.28 billion cash; ③ the symbol has had stable profits in the past two years, while yueyang forest & paper's operation continues to be under pressure; ④ the symbol was divested by yueyang forest & paper in 2015 due to poor performance.

cls.cnNov 26 08:35 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET

The pesticide market downturn dragged aba chemicals corporation into losses for five consecutive quarters, but the amount of losses narrowed. Interpretations of financial statements.

①Aba Chemicals Corporation has been operating at a loss for five consecutive quarters in Q3, but the amount of loss has narrowed compared to the first two quarters of this year. ② The pesticide industry is still at a low level, and the market situation for the company's main product, chlorfenapyr intermediate, has dropped significantly within one year. ③ The company's top ten shareholders changed in Q3, with a new institution shareholder and 'northbound funds' entering.

cls.cnOct 23 11:16 ET

It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.

①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.

cls.cnOct 18 01:13 ET

Non-public offering of information disclosure violations, yueyang forest & paper's controlling shareholder receives warning letter | Quick Read Announcement

①As a result of the previous issuance of additional shares, there were violations in the disclosure process, and the direct controlling shareholder of yueyang forest & paper received a warning letter. ②Affected by the industry downturn, the gross margin of new projects undertaken has decreased compared to previous years, and Chengtong Kaisheng's net income in H1 of this year has changed from profit to loss.

cls.cnSep 18 10:24 ET